Progesterone supplementation does not PROLONG pregnancy in women at risk for preterm birth: What do we do now?

What is the future for 17P now that a required trial for the drug’s efficacy showed that its use did not reduce preterm birth, neonatal morbidity, or fetal/early infant deaths—and an FDA advisory committee recommended withdrawal of the drug’s approval?

Read the full article here

Related Articles